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Resveratrol (RSV), naturally found in plants, is known to have health benefits and has been proposed as a potential anticancer
and cardioprotective drug. However, due to its molecular structure, it undergoes rapid metabolism in the body resulting in low
bioavailability. Novel polymeric methoxy-poly(ethylene glycol)-block-poly(𝜀-caprolactone) (mPEG-PCL) RSV conjugates with
varying PCL chain lengths have been synthesised and formulated intomicelles and/or nanoparticles for preliminary in vitro stability
studies. RSV conjugated withmPEG2000-PCL9500 was found to have improved solubility and stability of RSV as compared to RSV
alone. The length of the PCL chain was found to affect the micelle formation, hence the stability in physiological buffers and rat
plasma.
1. Introduction
RSV (trans-3,4󸀠,5-trihydroxystilbene, 1) is a polyphenolic [1]
phytoalexin naturally found in plants and major dietary
sources including grapes [2], red wine [3], peanuts, and root
extracts of Polygonum cuspidatum [4]. It possesses antiox-
idant, anticancer, antiangiogenic, and anti-inflammatory
activity [5, 6]. However, its poor solubility (0.03 g/L in
water) and rapid metabolism in the body have resulted in
limited clinical applications [7]. Although the nature of the
RSV molecule allows high biological absorption due to its
lipophilic nature, its polyphenolic nature leads to an extensive
metabolism in vivo resulting in almost no oral bioavailability
[8]. Pharmacokinetic studies in Wistar rats showed a half-
life of 7.8 minutes following intravenous administration [9]
whilst, in a Phase I clinical study on RSV dose escalations
and bioavailability in humans, no parent compound and only
metabolites were detected in blood as early as 15 minutes
postoral dosing [8].
The activity of RSV is highly dependent on its molecular
structure. A significant difference in anticancer activity was
found when the stereoisomers of RSV (trans and cis) were
tested on endothelial GM7373 cells [10]. The position of
the hydroxyl group on the stilbene ring also influences
the activity and potency of the compound [11]. An alteration
to the structure of RSV by the addition or replacement
with functional groups can increase or decrease activity [12].
However, research has shown increase in bioavailability and
efficacy of RSV in nanocarrier systems such as solid lipid
nanoparticles (SLNs) [13], liposomal nanoparticles [14, 15],
hydroxypropyl-beta-cyclodextrin (HP-𝛽-CD) particles [16],
nanoemulsions [17], copolymer nanoparticles [18, 19], and
chitosan-biotin nanoparticles [20]. In addition, conjugation
of various biocompatiblematerials to RSVhas been evaluated
for regeneration and mineralization of bone [21], anticancer
properties [22], and solubility [23].
Shao et al. [18] showed higher loading capacity and better
efficacy against glioma cells when RSV is encapsulated into
nanosized amphiphilic mPEG-PCL particles, whereas Tang
et al. [24] demonstrated better anticancer activity in poly-
meric conjugated curcumin, a similar molecular structure to
RSV. Previously, we demonstrated that conjugation of RSV
to mPEG-poly(lactide) (mPEG-PLA) with an ester linkage
reduced RSV metabolism and improved its pharmacokinetic
profile [25]. Therefore, there is a need for conjugated RSV
formulated into nanocarrier systems in order to possibly
increase its activity and overcome its poor solubility for ther-
apeutic application. RSV was conjugated to mPEG-PCL due
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to its different crystalline and hydrophobic nature compared
to mPEG-PLA [26] which may influence its nanoparticle
formation and in vitro properties. In this paper, a series of
novel amphiphilic mPEG-PCL RSV conjugates were syn-
thesized and formulated into micelles and/or nanoparticles.
These particles/micelles were then characterised and tested
for stability.
2. Experimental
2.1. Materials. Methoxy-poly(ethylene glycol) (mPEG) (𝑀
𝑤
2,000Da), 𝜀-caprolactone (𝜀-CL), tin (II) ethylhexanoate,
glutaric anhydride, triethylamine, pyrene, and pyridine
were obtained from Sigma-Aldrich (Australia). Trans-RSV
was purchased from DND PharmaTech Co., Inc., Shang-
hai, China (99% purity). (3-Dimethylaminopropyl)-𝑁󸀠-
ethylcarbodiimide hydrochloride (EDC.HCl) was purchased
from GL Biochem, Shanghai, China. All materials were used
without further purification or modification. Plasma from
outbred rats was purchased from the Animal Resources
Centre (ARC, Western Australia, Australia) collected in a
sodium citrate blood collection tube.
2.2. Methods
2.2.1. General. Proton NMR (nuclear magnetic resonance,
Bruker, 400MHz, Germany) spectra were obtained using
deuterated chloroform (CDCl
3
) or deuterated dimethyl sul-
foxide (𝑑
6
-DMSO) as a solvent. Peak positions and areas were
analysed to determine the degree of polymerization using
TopSpin™ v3.2 software and comparing integrals of peaks
from the PCL block and PEG block.
Gel permeation chromatography (GPC, Agilent; Santa
Clara, CA, USA) with a Jordi Gel DVB organic column
(5 𝜇m, 1000 Å, 25 cm × 4.6mm; Bellingham, MA, USA)
was used to measure the time-dependent molecular weight
changes of mPEG-PCL copolymers. A copolymer solution
(approximately 1mg/L) was prepared in tetrahydrofuran (as
the mobile phase of GPC) for the measurements. The elution
rate of the mobile phase was 1.2mL/min and poly (ethylene
glycol) standards in the range of 985–42700 g/mol was used
formolecular weight calibration. Detection was by an Agilent
model G1362A refractive index detector with a detector cell
temperature of 40∘C.
High-performance liquid chromatography (HPLC, Agi-
lent; Santa Clara, CA, USA) with Alltech Apollo C18 column
(150 × 4.6mm, 5 𝜇m; Columbia, MA, USA) was used to
analyse polymeric RSV conjugates and RSV. Analysis was
carried out using a mobile phase gradient of solution A (0.1%
v/v formic acid in acetonitrile) and solution B (0.1% v/v
formic acid in water). Absorbance was monitored at 307 nm
using a UV detector for RSV and fluorescence was measured
at 307 nm (ex) and 400 nm (em) using a fluorescence detector
for RSV polymeric conjugates. All calculations were carried
out using peak areas.
Nanoparticle size and size distribution were determined
by photon correlation spectroscopy using aZetasizer 3000HS
(Malvern Instruments, Malvern, Worcestershire, UK). The
measurements were performed at 25∘Cwith a detection angle
of 90∘, and the raw data were subsequently correlated to Z
averagemean size using a cumulative analysis by theZetasizer
3000HS software package. Each sample was measured 10
times. The zeta potential of particles was determined by
laser Doppler anemometry using a Zetasizer 3000HS. For
each sample, the mean ± SD of 3 repeat measurements was
established.
2.2.2. Synthesis of mPEG-PCL. mPEG-PCL with varying
PCL chain lengths was synthesized under vacuum via ring-
opening polymerization. For the synthesis of mPEG2000-
PCL5100, mPEG (15.2 g, 7.6mmol) was used as a macroini-
tiator and 𝜀-CL (25.7 g, 225mmol) was added as a monomer
whereas tin (II) ethylhexanoate (10% w/w mPEG, 1.5 g) was
added as a catalyst into a round bottom flask. The reaction
mixture was sealed under vacuum and stirred at 150∘C for
24 h. The reaction mixture was then allowed to cool and
minimal amount dichloromethane was added to dissolve the
reaction mixture. The flask was resealed and allowed to sit
at room temperature for 4 h. Excess ice-cold ether was then
added to precipitate the copolymer and the flask was resealed
and left in the fridge overnight to allow further precipitation.
The precipitate was filtered under vacuum to afford a cream-
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O-). Varying PCL chain lengths were
achieved by adjusting the mPEG : 𝜀-CL w/w feed ratio
(Table 1).
2.2.3. Synthesis of the Glutarate Ester of mPEG-PCL (mPEG-
PCL-glu). mPEG-PCL5100 (5.1 g, 2.6mmol), glutaric anhy-
dride (1.5 g, 13.1mmol), and triethylamine (0.4mL) were
dissolved in anhydrous toluene in a round bottom flask
and stirred under vacuum at 90∘C for 8 h. The reaction
mixture was cooled and dissolved in minimal amount of
dichloromethane and allowed to stand at room temperature
for 1 h. Excess ice-cold ether was then added to precipitate
a cream-coloured product (5.2 g, 100%). 1H NMR (CDCl
3
,

































































2.2.4. Synthesis of mPEG-PCL RSV Prodrugs (mPEG-
PCL-glu-RSV 2). The conjugation was achieved by a
carbodiimide coupling reaction. Excess amount of RSV
was added to mPEG-PCL5100-glu (5.3 g, 0.7mmol) and
EDC.HCl (2.6 g, 13.5mmol) in pyridine (20mL) in a round
bottom flask. The reaction mixture was stirred at room
temperature in the dark under vacuum for 48 h.The reaction
mixture was then dissolved in dichloromethane (15mL)
and washed once with 0.1M hydrochloric acid and twice
with 10% copper (II) sulphate aqueous solution diluted five
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Table 1: Synthesised copolymers with varying mPEG : 𝜀-CL w/w
feed ratio.












times in 0.1M hydrochloric acid. The organic layer was
collected and dried with sodium sulphate and filtered. The
filtrate was then precipitated with excess ice-cold ether to
afford a brown solid (0.4 g, 7.3%). 1H NMR (𝑑
6
-DMSO,
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O-), 𝛿 6.1 (s, 1H, H4), 𝛿 6.4 (s,
2H, H2/6), 𝛿 7.0 (s, 2H, alkenyl Hs), 𝛿 7.1–7.6 (dd, 4H,
H2󸀠/3󸀠/5󸀠/6󸀠), and 𝛿 9.6 (s, 2H, -OH) (Scheme 1).
2.2.5. Preparation and Characterisation of Conjugate Micelles
and/or Nanoparticles. RSV conjugates micelles were pre-
pared by self-assembly and a solvent diffusion method.
mPEG2000-glu-RSV was prepared by self-assembly in
MilliQ water and then characterised. Other copolymer con-
jugates were dissolved in organic solvent (5mg/mL) and
dispersed using an ultrasonic water bath. The organic phase
was added to known amounts ofMilliQwater and the organic
phase was evaporated by bubbling inert nitrogen through.
MilliQ water was added to make up to desired concentration.
Size and zeta potential of micelles were then measured and
subsequently, the micelles were subjected to stability studies.
2.2.6. Stability of mPEG-PCL-RSV Conjugates in Physiological
Buffers. Micelle stocks of 50mg/mL (3.5–21.5mM) were
diluted five times into acetate buffer pH4.5 and phosphate
buffer pH7.2. Aliquots were divided into Eppendorf tubes for
each time point to avoid evaporation and exposure to light.
All samples were then incubated at 37∘C in the dark. At each
time point, an aliquot of micelles in each physiological buffer
was diluted with 50 : 50 v/v acetonitrile : water for HPLC
Table 2: Copolymer yields and molecular weight comparisons
between NMR and GPC.
Copolymer Yield (%) NMR GPC
mPEG2000-CL 99.5 110 160
mPEG2000-PCL300 96.9 300 310
mPEG2000-PCL550 95.6 500 540
mPEG2000-PCL900 95.4 1200 900
mPEG2000-PCL1300 98.0 1700 1300
mPEG2000-PCL5100 72.8 5700 5100
mPEG2000-PCL9500 71.9 10700 9530
mPEG2000-PCL13000 79.4 12100 12930
7.5





Figure 1: 1H NMR spectra (400MHz) of synthesised mPEG-PCL-
glu-RSV in 𝑑
6
-DMSO. Key: † = 𝑑
6
-DMSO, ‡ = H
2
O.
analysis. Peak areas of conjugates of each time point were
analysed and data was presented as a percentage change in
concentration over time.
2.2.7. Stability of mPEG-PCL-RSV Conjugates in Rat Plasma.
The stability of the ester linkages in the conjugates was
assessed against the plasma esterases in rat plasma. 10mg/mL
(0.7–4.3mM) conjugate micelles were incubated in rat
plasma at 37∘C in the dark. Aliquots of plasma sample
(100 𝜇L) were prepared for each time point to avoid evap-
oration. At each time point, an aliquot of plasma was
diluted ten times with cold acetonitrile to precipitate plasma
proteins. The mixture was centrifuged at 10,000 rpm for 5
minutes. The supernatant was then diluted with 50 : 50 v/v
acetonitrile : water and analysed by HPLC. Peak areas of
conjugates of each time point were analysed and data was
presented as a percentage decrease over time.
3. Results and Discussion
3.1. Syntheses of Polymeric RSV Conjugates. Both PEG and
PCL are known to be biocompatible and biodegradable
[27] and hence would be suitable for the purpose of our

























Table 3: Polymeric conjugate micelles and nanoparticles size and zeta potential.
Polymeric conjugate Size (nm) Polydispersity index Zeta potential (mV)
mPEG2000-glu-RSV 369.2 ± 11.3 0.21 ± 0.05 3.7 ± 1.6
mPEG2000-CL-glu-RSV 226.2 ± 16.8 1 0.4 ± 1.6
mPEG2000-PCL300-glu-RSV 128.2 ± 28.4 0.9 ± 0.096 4.2 ± 1.6
mPEG2000-PCL550-glu-RSV 462.8 ± 55.8 1 2.5 ± 45.2
mPEG2000-PCL1300-glu-RSV 471.1 ± 16.1 0.475 ± 0.37 4.2 ± 1.6
mPEG2000-PCL5100-glu-RSV 657.5 ± 53.2 0.875 ± 0.217 24.8 ± 6.3
mPEG2000-PCL9500-glu-RSV 57.8 ± 0.2 0.409 ± 0.008 3.4 ± 1.6
mPEG2000-PCL13000-glu-RSV 218.4 ± 0.6 0.138 ± 0.066 5.6 ± 1.4
work. The syntheses of all copolymers were straight-for-
ward and gave high yields (>80%); however, the synthesis of
mPEG-PCL with higher PCL chain lengths produced lower
yields (Table 2). The molecular weight of PCL was deter-
mined by NMR and GPC by comparison with the known
molecular weight of PEG. The degree of polymerization of
the PCL was calculated by comparing integral intensity of
characteristic resonance of the PCL at 2.2 ppm (-C(=O-CH
2
)




-) in the 1H
NMR spectrum. The molecular weight of copolymers was
determined against the PEG standards calibration curve by
GPC analysis. Results from GPC were found to be consistent
with 1H NMR data (Table 2).
Using the various PCL chain lengths of mPEG-PCL
copolymers, RSV was conjugated with a glutarate ester link-
age. The aliphatic ester linkage is hydrolysable which allows
the RSV moiety to be released during in vivo use [21]. The
glutarification of the copolymers was confirmed by compar-



















-). The NMR analysis (Figure 1) of con-
jugates indicated the product is a mixture of conjugates 4󸀠-
mPEG-PCL-glu-RSV (about 45%), 3-mPEG-PCL-glu-RSV
(about 18%), and unconjugated RSV (37%) (Scheme 2). Since
HPLC analysis was able to separate and quantify free RSV and
polymeric conjugate, further purification was not performed.
3.2. Characterisation of Polymeric RSV Conjugate Micelles.
Table 3 reveals the size and polydispersity index of all
polymeric conjugate micelles prepared by self-assembly and
solvent diffusion method.
Micelles and/or nanoparticles were of submicron size;
however, there was no correlation between PCL chain length
and the size of the micelles and/or nanoparticles.This may be
due to the effect of the PCL chain length on the hydrophilic-
lipophilic balance of the conjugate, hence, the formation of
micelle and/or nanoparticles. Lowmagnitude zeta potential is
expected as there is no charged species present with polymers
and drug. With the right hydrophilic-lipophilic balance, the
conjugate should form polymeric micelles with reasonable
stability because of the presence of mPEG on the surface of
polymeric micelles. Most micelles/nanoparticles are found
to be unstable after 24 h observed by aggregation and/or
precipitation.These unstable formulations, indicated by large
polydispersity index (PDI), may require stabilising agents
such as polyvinyl alcohol (PVA) which adsorbs onto the sur-
face of micelles/nanoparticles to prevent their aggregation.
3.3. Stability in Physiological Buffers and Rat Plasma. Table 4
shows the stability of each conjugate in physiological buffers
and outbred rat plasma. Stability was tested in rat plasma
which contains high levels of carboxylesterase [28] which
hydrolyses the ester linkage in the RSV conjugates. The final
column shows the half-life (𝑡
1/2
) of each conjugate in rat
plasma. The half-life of RSV is known to be 7.8 minutes in
Wistar rats [9]. The conjugate micelle with PCL chain length
of 9500Da showed the best stability in plasma compared to
others and slightly better than the reported RSV data. Our
previous work done on RSV with mPEG-PLA conjugates
with succinate linkage showed a different outcome [25]. This
suggests that the type polymer, polymer chain length, and
linkage are important in determining the chemical stability
of the conjugates.
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Table 4: Chemical stability of conjugates in physiological buffer at 24 h and rat plasma.
Polymeric conjugate MilliQ water Acetate buffer pH 4.5 Phosphate buffer pH 7.2 𝑡
1/2
in rat plasma (min)
mPEG2000-glu-RSV >65%∗ >95% >40% 3
mPEG2000-CL-glu-RSV >80% >95% >95% 5
mPEG2000-PCL300-glu-RSV n/d∗∗ n/d n/d 3
mPEG2000-PCL550-glu-RSV n/d n/d n/d 3
mPEG2000-PCL1300-glu-RSV n/d n/d n/d 3.5
mPEG2000-PCL5100-glu-RSV >80% >80% >85% 4
mPEG2000-PCL9500-glu-RSV >95% >90% >90% 10
mPEG2000-PCL13000-glu-RSV >35% >30% >40% 8
∗Value represents percentage of original concentration at 24 h; ∗∗n/d: no data.
4. Conclusion
Conjugation of RSV to copolymers has overcome the poor
solubility issue of RSV by formulating into nanosized par-
ticles. In this paper, a series of mPEG-PCL conjugated RSV
were synthesized and only one of those with high molecular
weight of PCL was found to slightly improve the stability of
RSV in plasma as shown in preliminary stability tests. Based
on these results and also previous work, further formulation
studies and biological evaluation of the conjugates are war-
ranted.
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